Oncology Daily Report: 01/03/2024

A total of five clinical trials were identified. these included:

A Phase I clinical trial on 45 patients with advanced gastrointestinal cancers investigating the use of Minnelide. Patients included those with pancreatic cancer, colorectal cancer, and other GI tumors.

A Phase III randomized controlled trial on 553 patients with small-sized non-small-cell lung cancer (NSCLC). The study compared segmentectomy and lobectomy to analyze overall survival rates, causes of death, and recurrence patterns.

Study 3: A Phase Ib clinical trial on 22 patients with esophageal squamous cell cancer (ESCC). The study evaluated a chemotherapy-free regimen of neoadjuvant radio-immunotherapy (NRIT).

A Phase I trial on 18 patients with acute lymphoblastic leukemia (ALL) post allogeneic hematopoietic transplant (alloHCT). It focused on the use of low-dose inotuzumab ozogamicin (INO) to prevent relapse.

A Phase 1b clinical trial on 108 patients with EGFR-mutant non-small-cell lung cancer (NSCLC) that had MET and AXL dysregulations. The study tested the combination of ningetinib and gefitinib.

These studies cover a range of cancer types and treatment approaches, reflecting ongoing efforts to improve oncological outcomes through targeted therapies and novel treatment regimens.